Career Profile
Dr. Nilufer Avci is a highly qualified and skilled oncologist in Turkey. She specializes in the area of medical oncology. She offers a range of oncology care services for cancers of breast, lungs, gastrointestinal tract, bladder and brain, to name a few. Associate Professor Nilufer Avci has obtained medical degrees from the renowned institutions of the country. She has worked at several top-tier hospitals in Turkey over her vast medical experience. She has been actively involved in research and participated in various projects as Co-investigator and Principal Investigator. Dr. Nilufer Avci has published several articles and papers in reputed journals. She is also a member of many important medical societies and associations.
Education & Training
Graduation: Cumhuriyet University School of Medicine (1990-1996)
Postgraduation: Residency at Kocaeli University School of Medicine, Department of Internal Medicine Residency Program (1998-2002)
Uludag University School of Medicine, Department of Medical Oncology Residency Program (2008-2012)
Experience
- Kocaeli University, School of Medicine, Internal Medicine, Research Assistant (1998-2002)
- Kocaeli State Hospital, Internist (2002-2008)
- Uludağ University School of Medicine, Department of Medical Oncology (2008-2012)
- Balıkesir State Hospital, Department of Medical Oncology (2012-2014)
- Ali Osman Sonmez Oncology Hospital (2014-2016)
- Balıkesir University, Department of Medical Oncology, Associate Professor of Medicine (2016-2017)
- Associate Professor Medical Park Bursa, Associate Professor of Medicine (2017-2018)
- Medicana Bursa Hospital, Department of Medical Oncology, M.D. Associate Professor of Medicine (2018-present)
Co-investigator in Projects:
- Studies moderated by Prof. Türkkan Evrensel, M.D.
- Novartis “CRAD001L2201” A Randomized, Open-Labeled, Multi-center Phase II Study Comparing Interferon Alpha 2a Plus Bevacizumab and Bevacizumab Plus RAD001 in First-line Treatment of Patients with Metastatic Clear Cell Renal Cancer (Randomized Study)
- Boehringer Ingelheim 1200.125 LUX-Lung 8: A randomized, open-labeled, Phase III study comparing Erlotinib and Afatinib in Second-line treatment following first-line platinum-based chemotherapy for patients with advanced squamous cell lung cancer.
Principal Investigator in Projects:
Roche ML28579 Onko-Registry Study: A Registry Study on Prevalence of Non-small Cell Lung Cancer, Colon Cancer, Breast Cancer, Stomach Cancer and Malignant Melanoma and Diagnosis and Treatment Characteristics of These Cancers
Clinical Focus
- Medical Oncology
- Breast cancer treatment
- Lung cancer treatment
- Stomach cancer treatment
- Pancreas cancer treatment
- Sarcomas cancer treatment
- Prostate cancer treatment
- Bladder cancer treatment
- Pain and nutritional therapy in cancer patients
- Brain tumors
- Colorectal cancer